PubRank

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD)

Clinical Trial ID NCT00379769

PubWeight™ 28.56‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00379769

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 8.54
2 Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007 7.86
3 Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010 2.68
4 Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med 2014 2.67
5 Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010 1.38
6 Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005 1.09
7 Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007 1.08
8 Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol 2008 0.99
9 Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform 2014 0.89
10 Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines? Front Cell Neurosci 2014 0.85
11 Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011 0.83
12 Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetol 2014 0.76
13 Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus. Braz J Med Biol Res 2013 0.76
Next 100